Benin poised to join elite oms certified health regulators

Bénin’s health sector undergoes rigorous WHO evaluation

The Bénin Agency for Medicines and Health Products (ABMed) underwent a comprehensive assessment by an eight-member delegation from the World Health Organization (WHO) from 6 to 9 July 2026. This in-depth review examined the country’s regulatory framework, operational procedures, and compliance with global pharmaceutical standards.

Every facet of ABMed’s operations was scrutinized, including drug licensing, market surveillance, pharmacovigilance, and clinical trials. The goal was clear: to verify that Bénin’s health system aligns with the strictest international benchmarks. The findings, presented on 9 July in Cotonou, revealed significant progress, signaling that the nation is on the cusp of securing a Niveau de Maturité 3 (NM3) certification.

What does WHO’s NM3 certification mean for Bénin?

The NM3 level, as defined by the WHO, is reserved for countries with a stable, fully functional, and integrated pharmaceutical regulatory system. Achieving this milestone means Bénin’s authorities can exert full control over medicines circulating within its borders, ensuring public access to safe, effective, and high-quality treatments.

Beyond safeguarding public health, this certification carries substantial economic and geopolitical advantages. It enhances trust among international partners, encourages local drug production, and simplifies cross-border trade. Most importantly, it represents a decisive blow against the scourge of counterfeit medicines plaguing the region.

A decade of reform culminates in global recognition

During the evaluation’s closing ceremony, Bénin’s Minister of Health, Professor Benjamin Hounkpatin, praised the dedication of ABMed’s teams and the sweeping reforms implemented since 2017. The transformation began with the restructuring of the former pharmacy directorate into an autonomous agency, accompanied by tighter legislation to enforce compliance and accountability.

The Minister reaffirmed the government’s unwavering commitment to guiding ABMed toward full NM3 certification, emphasizing that this achievement is not an endpoint but a foundation for future advancements in healthcare governance.

Bénin’s rise as a regional health governance leader

If the final assessment confirms NM3 status, Bénin will join Senegal as the only francophone countries in West Africa to attain this elite classification. This milestone would cement its role as a hub for best practices in health regulation across the subregion.

The journey underscores a powerful message: with strong political will and technical rigor, African nations can elevate their institutions to meet the world’s highest standards.

A new chapter in public health for Bénin

The July 2026 WHO mission marks a watershed moment for Bénin’s healthcare system. While the preliminary results are promising, ABMed must now implement the remaining recommendations to secure official certification. The path to NM3 status proves that patient safety and pharmaceutical sovereignty are achievable goals—within reach, not just on the horizon.